Laurion Capital Management LP Takes $2.76 Million Position in Aldeyra Therapeutics, Inc (ALDX)
Laurion Capital Management LP acquired a new stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 200,000 shares of the biotechnology company’s stock, valued at approximately $2,760,000.
A number of other institutional investors have also recently bought and sold shares of ALDX. FMR LLC lifted its stake in Aldeyra Therapeutics by 59.1% in the third quarter. FMR LLC now owns 2,564,333 shares of the biotechnology company’s stock valued at $35,388,000 after purchasing an additional 953,022 shares during the last quarter. BlackRock Inc. lifted its position in shares of Aldeyra Therapeutics by 1,881.2% during the second quarter. BlackRock Inc. now owns 780,744 shares of the biotechnology company’s stock worth $6,207,000 after acquiring an additional 741,337 shares in the last quarter. EAM Investors LLC purchased a new stake in shares of Aldeyra Therapeutics during the third quarter worth $4,307,000. Gilder Gagnon Howe & Co. LLC purchased a new stake in shares of Aldeyra Therapeutics during the third quarter worth $3,010,000. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Aldeyra Therapeutics during the second quarter worth $1,335,000. Institutional investors and hedge funds own 69.10% of the company’s stock.
NASDAQ:ALDX opened at $9.23 on Friday. The firm has a market cap of $258.51 million, a price-to-earnings ratio of -6.59 and a beta of 0.81. Aldeyra Therapeutics, Inc has a 1 year low of $6.20 and a 1 year high of $16.70. The company has a current ratio of 4.82, a quick ratio of 4.82 and a debt-to-equity ratio of 0.03.
Several equities research analysts have issued reports on ALDX shares. Cantor Fitzgerald set a $30.00 target price on Aldeyra Therapeutics and gave the stock a “buy” rating in a research report on Thursday, October 4th. ValuEngine upgraded Aldeyra Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, September 20th. Citigroup started coverage on Aldeyra Therapeutics in a research report on Tuesday. They set a “buy” rating and a $23.00 target price on the stock. Stifel Nicolaus increased their target price on Aldeyra Therapeutics from $16.00 to $36.00 and gave the stock an “in-line” rating in a research report on Wednesday, September 26th. They noted that the move was a valuation call. Finally, Zacks Investment Research downgraded Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $24.64.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.
Further Reading: What is the Federal Reserve?
Want to see what other hedge funds are holding ALDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aldeyra Therapeutics, Inc (NASDAQ:ALDX).
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.